Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FMPV-1 + Sargramostim |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FMPV-1 | FMPV 1|FMPV1 | TGFBR2 inhibitor 1 | Limited information is currently available on FMPV-1, a putative vaccine targeting TGFRB2 frameshift mutations (Dec 2022). | |
Sargramostim | Leukine | GM-CSF|Prokine |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05238558 | Phase I | FMPV-1 + Sargramostim | Safety and Immune Response to FMPV-1 | Completed | GBR | 0 |